← 返回

IL-7/IL-7R 及其重组衍生物在胶质瘤中的治疗价值:叙述性综述

英文原题:The Therapeutic Values of IL-7/IL-7R and the Recombinant Derivatives in Glioma: A Narrative Review.

查看英文原题

The Therapeutic Values of IL-7/IL-7R and the Recombinant Derivatives in Glioma: A Narrative Review.

PubMed 2023/08/01(内容时间) J Interferon Cytokine Res Q4 · IF 1.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

白细胞介素-7(IL-7)通过调节淋巴细胞的发育和稳态,对维持免疫系统的防御功能至关重要。研究结果表明,基于IL-7/IL-7受体(IL-7R)的免疫疗法对多种恶性肿瘤具有高效性,并已在动物模型和人类中得到证实。近年来,通过引入表达C7R的嵌合抗原受体(CAR)-T细胞和长效IL-7激动剂如NT-I7(rhIL-7-hyFc,Efineptakin alfa),胶质瘤患者的无进展生存期和总生存期显著延长。然而,基于IL-7的免疫疗法对肿瘤细胞化疗耐药性(与化疗药物同时使用时)的影响仍不明确,需要进一步研究。本文首先综述IL-7/IL-7R在肿瘤中的病理生理作用,重点关注胶质瘤。随后,讨论IL-7/IL-7R及其重组衍生物在胶质瘤中的治疗价值。

展开英文摘要原文

Interleukin-7 (IL-7) is essential for maintaining the immune system's defense functions by regulating the development and homeostasis of lymphocytes. Findings have shown the high efficacy of IL-7/IL-7 receptor (IL-7R)-based immunotherapy on various malignancies, with confirmation in both animal models and humans.

In recent years, the progression-free survival and overall survival of patients suffering from gliomas significantly increased by introducing C7R-expressing chimeric antigen receptor (CAR)-T cells and long-acting IL-7 agonists such as NT-I7 (rhIL-7-hyFc, Efineptakin alfa).

However, the effect of IL-7-based immunotherapies on the resistance of tumor cells to chemotherapy (when used simultaneously with chemotherapy agents) is still ambiguous and requires further studies. This article first reviews the pathophysiological roles of IL-7/IL-7R in tumors, focusing on gliomas. Subsequently, it discusses the therapeutic values of IL-7/IL-7R and the recombinant derivatives in gliomas.

论文信息

作者
Hesari M、Attar Z、Soltani-Shirazi S、Keshavarzian O、Taheri R、Tabrizi R、Fouladseresht H
第一作者单位
Tabriz University of Medical Sciences, Tabriz, Iran.Iran
通讯作者单位
Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.Iran
文献类型
综述
期刊
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2023 Aug
原文标识
PubMed 37566474 · DOI 10.1089/jir.2023.0050